<DOC>
	<DOCNO>NCT02184819</DOCNO>
	<brief_summary>The investigator want test hypothesis infusion levosimendan start prior CABG surgery reduce incidence severity low cardiac output syndrome patient poor LV function ( EF 40 % less ) .</brief_summary>
	<brief_title>Preoperative Levosimendan CABG Patients With Poor LV Function</brief_title>
	<detailed_description>Background : Patients ejection fraction le 40 % high risk develop postoperative low cardiac output syndrome ( LCOS ) . Despite use potent inotropic agent even ventricular mechanical assist device , mortality rate patient remain high ( 17 38 % ) . Their hospital stay also prolong cost care population increase . Two study suggest post-operative administration levosimendan could reduce hospital length stay long term ( Day180 ) mortality patient LCOS . In addition study also suggest pre-operative infusion levosimendan ( pre-conditioning ) could reduce use inotropes mechanical assist device patient high risk develop LCOS . Unfortunately , data support beneficial effect levosimendan high risk cardiac surgery patient limit . Main goal : To evaluate efficacy pre-operative infusion levosimendan high risk patient ( EF less 40 % ) undergoing cardiac surgery ( CABG combine surgery : CABG valve replacement ) improve outcome . Secondary goal : To evaluate : 1 ) clinical safety pre-operative infusion levosimendan , 2 ) cost care levosimendan control group . Experimental setup : Prospective , multicenter , randomize versus placebo , double-blind trial . Treatment modality : levosimendan administer intravenous route , accord continuous infusion 0.1mcg/kg/min 24 hour . Levosimendan infusion ( 0.1mcg/kg/min ) start immediately induction anaesthesia . The delay infusion start skin incision estimate 30 60 min . The investigator decide skip bolus infusion frequently associate systemic hypotension , may result serious adverse event protocol exclusion . Study duration patient follow-up : Patients recruit 23 month . Individual follow-up last 6 month . Overall duration study 29 month .</detailed_description>
	<mesh_term>Simendan</mesh_term>
	<criteria>18 Years old schedule CABG CPB without asociated cardiac repair ejection fraction le 40 % sign informed consent preoperative renal failure ( creatinine clearance le 30 ml/min ) liver failure ( prothrombine time le 50 % absence vitamin K antagonist ) cardiac surgery without CABG pregnancy emergency surgery know allergy levosimendan severe hypotension prior surgery severe tachycardia prior history torsade de pointe dynamic obstruction od leave ventricular outflow tract lack sign informed consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>coronary artery bypass graft</keyword>
	<keyword>leave ventricular dysfunction</keyword>
	<keyword>low cardiac output syndrome</keyword>
	<keyword>levosimendan</keyword>
	<keyword>mortality</keyword>
	<keyword>inotropic agent</keyword>
	<keyword>cardiac mechanical assist device</keyword>
	<keyword>renal replacement therapy</keyword>
	<keyword>mechanical ventilation duration</keyword>
	<keyword>ICU stay</keyword>
</DOC>